Humana GLP-1 Coverage for Weight Loss (2026)
You have a Humana card and one question: will this plan pay for a GLP-1 medication to help you lose weight? For most Humana members, the card is a Medicare Advantage or Medicare drug plan card, and that shapes the answer. Here is what Humana’s own documents and Medicare’s rules say as of 2026-10-16, and how to find out where your plan stands.
Transformation Health is an independent guide, not a provider, and is not affiliated with Humana: we do not prescribe, sell medication, or work with insurance. This content is for general education and is not medical advice. Talk with a licensed provider about your situation.
The short answer
Humana Medicare plans generally do not cover GLP-1 medications for weight loss alone. As of 2026-10-16, Humana’s own Medicare page says “Standard Medicare Part D prescription drug plans don’t cover GLP-1 medications only for weight loss."[1] That is a federal rule, not a Humana choice: the Part D statute lets drug plans exclude drugs “when used for anorexia, weight loss, or weight gain."[2]
Three things sit outside that exclusion:
- Other medical uses. CMS lists type 2 diabetes, Wegovy to reduce cardiovascular risk, Zepbound for moderate to severe obstructive sleep apnea, and certain MASH (a liver condition) uses as eligible for Part D coverage.[3] Whether your Humana plan covers a given drug for one of those uses depends on its drug list (see the table below).
- The Medicare GLP-1 Bridge. A CMS demonstration from July 1, 2026 through December 31, 2027 for eligible Part D enrollees who want a GLP-1 for weight management. It runs outside your Humana plan’s benefit.[3][4]
- Paying without insurance. Manufacturer self-pay options and cash-pay programs do not involve Medicare rules at all.
Why Humana is mostly a Medicare question
Humana announced on February 23, 2023 that it would exit the employer group commercial medical business, covering all fully insured, self-funded, and Federal Employee Health Benefit medical plans, phased over 18 to 24 months.[5] In its annual report for 2025, Humana says it “finalized our exit” from that business during 2025.[6]
What remains is mainly government-funded coverage: Medicare Advantage and Medicare drug plans, Medicaid plans in several states, and administrative services for the TRICARE East Region.[6] If you have an older Humana employer card, it is worth checking whether that coverage is still active.
What Humana’s 2026 Medicare drug lists show
We checked three of Humana’s 2026 Medicare drug lists, each updated 10/01/2026: the Humana Value Rx Plan (PDP), the Humana Premier Rx Plan (PDP), and the HumanaChoice (PPO) plans.[7][8][9] Humana offers many plans, and drug lists differ, so treat this as a snapshot, not your plan’s terms.
| Question | What Humana’s documents and CMS say (as of 2026-10-16) |
|---|---|
| GLP-1s covered for weight loss alone? | No. Humana says standard Part D plans do not cover GLP-1s only for weight loss[1] |
| Wegovy on the drug list? | Not listed on any of the three drug lists we checked[7][8][9] |
| Zepbound on the drug list? | Not listed on any of the three drug lists we checked[7][8][9] |
| Ozempic and Mounjaro (type 2 diabetes)? | Listed on all three, on tier 3, with prior authorization and quantity limits[7][8][9] |
| Drug not on the list? | You or your prescriber can ask Humana for a formulary exception, with a supporting statement from your prescriber[7] |
| Exception decision time | Generally within 72 hours of the prescriber’s supporting statement, or 24 hours for an expedited request[7] |
| Is the Medicare GLP-1 Bridge a Humana benefit? | No. It operates outside the Part D benefit, though CMS uses Humana as its central processor[3] |
Humana’s Medicare page also says Part D may cover drugs like Ozempic and Wegovy “if prescribed for diabetes management or cardiovascular disease."[1] On the three drug lists we checked, Wegovy does not appear, so on those plans the route for a covered use would be a formulary exception. Humana says it generally approves exceptions only when the drugs on its list would not be as effective for you or would cause adverse effects.[7]
The other medical uses
These match uses on the FDA labels. Wegovy is approved, with diet and physical activity, to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight, and Wegovy injection to treat MASH with moderate to advanced liver fibrosis. Zepbound is approved to treat moderate to severe obstructive sleep apnea in adults with obesity.[10][11] Both labels carry a boxed warning about the risk of thyroid C-cell tumors. A licensed provider decides whether any of these uses applies to you.
The Medicare GLP-1 Bridge
As of 2026-10-16, CMS describes the Medicare GLP-1 Bridge as a short-term demonstration that gives eligible Medicare Part D beneficiaries access to certain GLP-1 drugs for weight management between July 1, 2026 and December 31, 2027.[4] It “will operate outside of the Medicare Part D benefit’s coverage and payment flow,” so your Humana plan does not need to opt in.[3]
One detail is specific to Humana. CMS says it is using Humana, the current administrator of the Limited Income Newly Eligible Transition (LI NET) program, as the central processor for the Bridge, handling prior authorization, claims, and pharmacy payment.[3] That is a role Humana performs for CMS. It does not make the Bridge part of your Humana plan, and eligibility is set by CMS.
Humana’s Medicare page says Bridge enrollees must be in a standalone drug plan (PDP) or a Medicare Advantage coordinated care plan with drug coverage, and must be diagnosed with obesity by a health care provider.[1] CMS also says people prescribed a GLP-1 for a use Part D already covers, such as type 2 diabetes or Wegovy for cardiovascular risk reduction, should get coverage through Part D, not the Bridge.[3] Our guides to the Medicare GLP-1 Bridge and Medicare Part D and GLP-1 coverage explain both in more detail. To find out whether the Bridge applies to you, contact CMS or call 1-800-MEDICARE.
What changed in 2025 and 2026
2025. Humana finalized its exit from employer group commercial medical plans.[6]
July 1, 2026. The Medicare GLP-1 Bridge started.[4]
October 1, 2026. The current versions of the three Humana drug lists we checked were updated, and none lists Wegovy or Zepbound.[7][8][9]
Drug lists can change on January 1 each year and from time to time during the year, as Humana’s own drug lists note.[7] A rule that applies this year is worth checking again at open enrollment.
Humana Medicaid and TRICARE
Humana Medicaid plans. Humana holds Medicaid contracts in states including Florida, Kentucky, Illinois, Indiana, Louisiana, Ohio, Oklahoma, South Carolina, Virginia, and Wisconsin.[6] Medicaid coverage of GLP-1s for weight loss follows each state’s rules, which differ by state. Call the member services number on your card.
TRICARE East. Humana provides administrative services for the TRICARE East Region under a Department of Defense contract that began January 1, 2025.[6] TRICARE pharmacy coverage is a separate program: TRICARE says “Express Scripts administers the TRICARE Pharmacy Program."[12] Our page on TRICARE GLP-1 coverage covers it.
How to check your own plan
You do not need to wait for a denial letter. Two questions, two places to ask.
For your Humana plan, call member services. Use the number on your Humana card and ask three questions. Is the GLP-1 medication my prescriber is considering on my plan’s drug list? If so, for which use, and what does prior authorization require? If not, how do I request a formulary exception? You can also search your plan’s drug list on Humana’s website.
For the Bridge, contact Medicare. The Bridge runs outside your Humana plan, so CMS or 1-800-MEDICARE is the place to ask whether it applies to you.
If you have type 2 diabetes, established cardiovascular disease, or diagnosed obstructive sleep apnea, ask your prescriber whether one of those uses fits your situation. Our guide to GLP-1 prior authorization walks through the documentation these requests usually need.
If your plan says no
What you do next depends on why the answer was no.
The request was for a covered use and was denied. This is often about documentation. You can ask Humana for a coverage decision or exception with a supporting statement from your prescriber, and Medicare drug plans have their own appeal process.[7] Our page on what to do when insurance denies your GLP-1 walks through reading a denial.
You want the medication for weight loss alone. A Humana Part D plan generally cannot cover it for that use, and an appeal cannot change a federal exclusion.[1][2] Check whether you qualify for the Medicare GLP-1 Bridge. Beyond that, the options are outside insurance:
- Manufacturer self-pay options. Novo Nordisk and Eli Lilly each publish self-pay terms, and the terms change. Manufacturer savings cards for people with commercial insurance generally exclude Medicare enrollees. Our page on GLP-1 savings programs compares the options.
- Cash-pay telehealth programs. Some prescribe brand-name medications and some prescribe compounded medications. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products.[13] Our page on compounded GLP-1 without insurance explains how that route works.
Prices vary by program, medication, and dose. Compare the total cost: medication, dose increases, visits, labs, shipping, membership fees, and cancellation terms. At most telehealth programs, a licensed provider reviews your health history and decides whether a prescription is appropriate. The full insurance coverage overview can help you weigh the options side by side.
Transformation Health does not accept payment from providers. How we make money.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedCitations
[1] Humana. “Does Medicare cover GLP-1 weight loss drugs?” Published 05/15/2026, updated 06/08/2026. Accessed 2026-10-16. https://www.humana.com/medicare/medicare-resources/does-medicare-cover-weight-loss-drugs
[2] 42 U.S.C. 1395w-102(e)(2)(A) (definition of covered Part D drug; exclusions), incorporating 42 U.S.C. 1396r-8(d)(2)(A). Accessed 2026-10-16. https://www.law.cornell.edu/uscode/text/42/1395w-102
[3] Centers for Medicare and Medicaid Services. “Medicare GLP-1 Bridge: Information for Part D Plans.” Page last modified 08/06/2026. Accessed 2026-10-16. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans
[4] Centers for Medicare and Medicaid Services. “Medicare GLP-1 Bridge.” Page last modified 07/13/2026. Accessed 2026-10-16. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
[5] Humana. “Humana to Exit Employer Group Commercial Medical Products Business.” Press release, February 23, 2023. Accessed 2026-10-16. https://news.humana.com/press-room/press-releases/2023/humana-to-exit-employer-group-commercial-medical-products.html
[6] Humana Inc. Form 10-K for the fiscal year ended December 31, 2025. U.S. Securities and Exchange Commission. Filed 2026-02-19. Accessed 2026-10-16. https://www.sec.gov/Archives/edgar/data/49071/000004907126000009/hum-20251231.htm
[7] Humana. 2026 Prescription Drug Guide, Humana Value Rx Plan (PDP), Formulary 26400. Updated 10/01/2026. Accessed 2026-10-16. https://assets.humana.com/is/content/humana/20260003PDG2640026Cpdf
[8] Humana. 2026 Prescription Drug Guide, Humana Premier Rx Plan (PDP), Formulary 26402. Updated 10/01/2026. Accessed 2026-10-16. https://assets.humana.com/is/content/humana/20260005PDG2640226Cpdf
[9] Humana. 2026 Prescription Drug Guide, HumanaChoice (PPO), Formulary 26408. Updated 10/01/2026. Accessed 2026-10-16. https://assets.humana.com/is/content/humana/20260015PDG2640826Cpdf
[10] Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information. U.S. Food and Drug Administration. Revised 06/2026. Accessed 2026-10-16. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf
[11] Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information. U.S. Food and Drug Administration. Revised 08/2026. Accessed 2026-10-16. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf
[12] TRICARE (Defense Health Agency). “Pharmacy.” Accessed 2026-10-16. https://www.tricare.mil/CoveredServices/Pharmacy
[13] U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” Accessed 2026-10-16. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
Important disclosures
Coverage information on this page is current as of 2026-10-16, is general and educational, and changes frequently. It does not represent the terms of your specific plan and is not legal advice. To verify coverage for your plan, call the member services number on your Humana card. For questions about the Medicare GLP-1 Bridge, contact CMS or call 1-800-MEDICARE.
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. transformationhealth.com is a website operated by Amerigo Health LLC. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication, and does not give medical advice. A licensed provider decides whether a prescription is appropriate. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy or Zepbound and may differ in formulation, purity, and potency. Wegovy and Ozempic are trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are trademarks of Eli Lilly and Company. Humana, HumanaChoice, and TRICARE are trademarks of their respective owners. Transformation Health is not affiliated with or endorsed by Humana, TRICARE, Express Scripts, Novo Nordisk, or Eli Lilly. Transformation Health does not accept payment from providers. How we make money.